Here are four points:
1. Wright Medical can now initiate commercial sale and distribution of the bone graft in the United States.
2. The bone graft is intended as an alternative to autograft for ankle and/or hindfoot fusion indications.
3. The bone graft features a combination of two components — recombinant human Platelet-Derived Growth Factor and Beta-tricalcium phosphate.
4. The bone graft has undergone clinical trial and testing, and the FDA’s PMA application approval indicates that the FDA has determined that the graft is safe and effective.
More articles on devices:
Integra LifeSciences acquires Tornier foot & ankle products ahead of Wright Medical merger: 5 key notes
4 notes about Genesys Spine ranking on Inc. 5000 List for 2nd year
Medtronic Q1 revenue soars 12%, Core Spine flat: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
